No­var­tis spot­lights its top 4 block­buster late-stage pipeline projects

Over the past year the R&D group at No­var­tis $NVS has de­vel­oped one of the most mus­cu­lar late-stage pipeline strate­gies in Big Phar­ma. They kept their lead in CAR-T and drove home the first ap­proval in the field, and they have 4 Phase III ef­forts un­der­way which they are show­cas­ing dur­ing to­day’s R&D day in Lon­don.

The spot­light il­lus­trates where this phar­ma gi­ant — one of the top three among the glob­al R&D play­ers with a bud­get of about $9 bil­lion — plans to in­vest the great­est en­er­gy in win­ning new ap­provals. And while a whole long slate of ri­vals are ei­ther strug­gling to demon­strate that they are on to new drugs of re­al im­por­tance or find some way to in­spire in­no­va­tion, No­var­tis de­vel­op­ment chief Vas Narasimhan is un­der­scor­ing with this list why he was se­lect­ed to take the CEO’s job.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER